The impact of medical visits for chemotherapy-induced anemia and neutropenia on the patient and caregiver: A national survey

Community Oncology

Volumn 1, Issue 4, 2004, Pages 211-217

  Fortner, Barry ^a,b,c   Tauer, Kurt ^a,d   Zhu, Ling ^a,d   Ma, Lea ^a,d   Schwartzberg, Lee S ^a,d  

^a Accelerated Community Oncology Research Network   (United States)

^b Accelerated Comm Oncol Res Netwk ^*  (United States)

^c West Clinic   (United States)

^d Hematology and Medical Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CAREGIVER; DIGESTIVE SYSTEM CANCER; DOCTOR PATIENT RELATION; FEMALE; GYNECOLOGIC CANCER; HEALTH SURVEY; HOSPITALIZATION; HUMAN; INFECTION; INTERVIEW; LEUKOCYTE COUNT; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; NURSE; OUTPATIENT; PATIENT CARE; PROSTATE CANCER; QUALITY OF LIFE; RETROSPECTIVE STUDY; REVIEW; UROGENITAL TRACT CANCER;

EID: 13844298694     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70825-7     Document Type: Review

References (38)

1. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34(3suppl2):13-19.
2. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-895.
3. Groopman JL, Itri L. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
4. Littlewood TJ, Bajetta E, Nortier JWR, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
5. Lind M, Vernon C, Cruikshank D, et al. The level of haemoglobin in anemic cancer patients correlates positively with quality of life. Br J Cancer 2002;86:1243-1249.
6. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-340.
7. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-170.
8. Fortner BV, Stolshek B, Schwartzberg LS, et al. Decline in absolute neutrophil count is associated with lower quality of life in cancer patients receiving docetaxel. In: Program/Proceedings of the 38th Annual Meeting of the American Society of Clinical Oncology; May 18-20, 2002; Orlando, Fla. Abstract 2808.
9. Okon TA, Fortner BV, Schwartzberg L, et al. Quality of life in patients with grade IV chemotherapy-induced neutropenia. In: Program/Proceedings of the 38th Annual Meeting of the American Society of Clinical Oncology; May 18-20, 2002; Orlando, Fla. Abstract 2920.
10. Lepage E, Gisselbrecht C, Haioun C, et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. Ann Oncol 1993;4:651-656.
11. Kwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990;8:963-977.
12. Epelbaum R, Faraggi D, Ben-Arie Y, et al. Survival of diffuse large cell lymphoma: a multivariate analysis including dose intensity variables. Cancer 1990;66:1124-1129.
13. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901-906.
14. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 1998;90:1205-1211.
15. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-1234.
16. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-3425.
17. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319-324.
18. Amman KS, Griffin JD, Elias A, et al. Effect of recombinant human granulocyte macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 1988;319:593-598.
19. Glaspy JA. Hematopoietic management in oncology practice, I: myeloid growth factors. Oncology (Huntingt) 2003;17:1593-1603.
20. Meehan K, Tchekmedyian S, Ciesla G, Kallich J, Erder MH, Smith R. The burden of weekly epoetin alfa injections to patients and their caregivers. In: Program/Proceedings of the 39th Annual Meeting of the American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract 2186.
21. Moore K, Fortner B, Okon T. The impact of medical visits on patients with cancer. Oncol Nurs Forum 2003;30:128. Abstract 73.
22. Payne S, Jarrett N, Jeffs D. The impact of travel on cancer patients' experiences of treatment: a literature review. Eur J Cancer Care 2000;9:197-203.
23. Glaspy JA, Tchekmedyian NS. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology (Huntingt) 2002;16(10 suppl 11):23-29.
24. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-731.
25. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35.
26. Fortner BV, Tauer K, Zhu L, et al. Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities. BMC Cancer 2004;4:22. Available at: http://www. biomedcentral.com/ 1471-2407/4/22. Accessed September 23, 2004.
27. Goodwin JS, Hunt WC, Samet JM. Determinants of cancer therapy in elderly patients. Cancer 1993;72:594-601.
28. Guidry JJ, Aday LA, Zhang D, Winn RJ. Transportation as a barrier to cancer treatment. Cancer Pract 1997;5:361-366.
29. Junor EJ, Macbeth FR, Barrett A. An audit of travel and waiting times for outpatient radiotherapy. Clin Oncol 1992;4:174-176.
30. Pearce S, Kelly D, Stevens W. "More than just money"-widening the understanding of the costs involved in cancer care. J Adv Nurs 2001;33:371-379.
31. Matthews BA, Baker F, Spillers RL. Oncology professionals and patient requests for cancer support services. Support Care Cancer 2004 June 8. (Epub ahead of print.)
32. Hinds C, Moyer A. Support as experienced by patients with cancer during radiotherapy treatments. J Adv Nurs 1997;26:371-379.
33. Lindley C, Vasa S, Sawyer WT, Winer EP. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol 1998;16:1380-1387.
34. Wagner L, Lacey MD. The hidden costs of cancer care: an overview with implications and referral resources for oncology nurses. Clin J Oncol Nurs 2004;8:279-287.
35. Moore KA. Breast cancer patients' out-of-pocket expenses. Cancer Nurs 1999;22:389-396.
36. Houts PS, Lipton A, Harvey HA, et al. Nonmedical costs to patients and their families associated with outpatient chemotherapy. Cancer 1984;53:2388-2392.
37. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000;18:3558-3585.
38. Anastasia PJ, Blevins MC. Outpatient chemotherapy: telephone triage for symptom management. Oncol Nurs Forum 1997;24(1 suppl):13-22.